B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund maintained its stake in Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 65,390 shares of the medical equipment provider’s stock at the end of the second quarter. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund’s holdings in Boston Scientific Corporation were worth $1,813,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. State of Alaska Department of Revenue acquired a new stake in Boston Scientific Corporation during the first quarter worth approximately $241,000. Profund Advisors LLC increased its stake in Boston Scientific Corporation by 15.3% in the first quarter. Profund Advisors LLC now owns 56,044 shares of the medical equipment provider’s stock worth $1,394,000 after buying an additional 7,423 shares during the last quarter. ProShare Advisors LLC increased its stake in Boston Scientific Corporation by 1.2% in the first quarter. ProShare Advisors LLC now owns 136,230 shares of the medical equipment provider’s stock worth $3,388,000 after buying an additional 1,602 shares during the last quarter. Breton Hill Capital Ltd. acquired a new stake in Boston Scientific Corporation during the first quarter worth approximately $224,000. Finally, Wetherby Asset Management Inc. increased its stake in Boston Scientific Corporation by 6.7% in the first quarter. Wetherby Asset Management Inc. now owns 13,265 shares of the medical equipment provider’s stock worth $330,000 after buying an additional 835 shares during the last quarter. Institutional investors and hedge funds own 91.62% of the company’s stock.

Boston Scientific Corporation (NYSE:BSX) opened at 26.72 on Friday. The firm has a market cap of $36.66 billion, a price-to-earnings ratio of 47.80 and a beta of 1.09. The firm has a 50-day moving average of $27.08 and a 200 day moving average of $26.22. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $28.51.

Boston Scientific Corporation (NYSE:BSX) last issued its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.01. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The company had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same period last year, the business earned $0.27 EPS. Boston Scientific Corporation’s quarterly revenue was up 6.2% compared to the same quarter last year. Analysts expect that Boston Scientific Corporation will post $1.26 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/26/b-s-pension-fund-trustee-ltd-acting-for-the-british-steel-pension-fund-holds-position-in-boston-scientific-corporation-bsx.html.

BSX has been the topic of a number of research reports. Oppenheimer Holdings, Inc. set a $27.00 target price on shares of Boston Scientific Corporation and gave the stock a “hold” rating in a report on Friday, April 28th. Evercore ISI boosted their price target on shares of Boston Scientific Corporation from $26.50 to $28.50 and gave the company an “outperform” rating in a report on Friday, April 28th. Cowen and Company boosted their price target on shares of Boston Scientific Corporation from $29.00 to $31.00 and gave the company an “outperform” rating in a report on Friday, April 28th. Stifel Nicolaus boosted their price target on shares of Boston Scientific Corporation from $28.00 to $30.00 and gave the company a “buy” rating in a report on Friday, April 28th. Finally, Zacks Investment Research upgraded shares of Boston Scientific Corporation from a “sell” rating to a “hold” rating in a report on Monday, May 1st. Six analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Boston Scientific Corporation presently has a consensus rating of “Buy” and a consensus target price of $30.06.

In related news, SVP Wendy Carruthers sold 12,433 shares of the stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $26.75, for a total value of $332,582.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP John Bradley Sorenson sold 7,900 shares of the stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $26.37, for a total value of $208,323.00. Following the completion of the transaction, the senior vice president now owns 21,680 shares in the company, valued at $571,701.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 207,625 shares of company stock worth $5,686,383. 0.74% of the stock is owned by company insiders.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.